No Data
No Data
Xinguang Pharmaceutical (300519.SZ) 2023 equity distribution: 4 yuan for every 10 shares
Xinguang Pharmaceutical (300519.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
Xinguang Pharmaceutical (300519.SZ) announced its 2023 annual results. Net profit of 64.3565 million yuan decreased by 40.86% year-on-year, and plans to distribute 4 yuan for every 10 shares
According to Zhitong Finance App, Xinguang Pharmaceutical (300519.SZ) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 270 million yuan, a year-on-year decrease of 23.07%; net profit attributable to shareholders of listed companies was 60.3565 million yuan, a year-on-year decrease of 40.86%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 60.1236 million yuan, a year-on-year decrease of 42.72%; the company plans to distribute a cash dividend of 4.00 yuan for every 10 shares to all shareholders. During the reporting period, the company's leading products were astragalus extract and muscle stretcher
Hefeng Investment, the majority shareholder of Xinguang Pharmaceutical (300519.SZ), reduced its holdings by 670,000 shares at the end of the reduction period
Xinguang Pharmaceutical (300519.SZ) announced that Shengzhou Hefeng Investment Co., Ltd., the shareholder of the company holds more than 5% of the shares...
Xinguang Pharmaceutical (300519.SZ): Has carried out scientific research cooperation with Zhejiang University of Traditional Chinese Medicine, Zhejiang University of Technology, Zhejiang Institute of Traditional Chinese Medicine, Zhejiang University, etc.
Gelonghui March 28 丨 An investor asked Xinguang Pharmaceutical (300519.SZ) on the investor interactive platform, “Please ask which medical college your company has cooperated with”. The company replied that the company has successively carried out scientific research cooperation with Zhejiang University of Traditional Chinese Medicine, Zhejiang University of Technology, Zhejiang Institute of Traditional Chinese Medicine, Zhejiang University, and Zhejiang University.
Xinguang Pharmaceutical (300519.SZ): Astragalus is not included in the 2023 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue
Gelonghui, Feb. 29丨Xinguang Pharmaceutical (300519.SZ) said on the investor interactive platform that Huangqi Shengmai Drink was not included in the 2023 edition of the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue.
Some Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) Shareholders Look For Exit As Shares Take 26% Pounding
The Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) share price has fared very poorly over the last month, falling by a substantial 26%. The drop over the last 30 days has capped off a tou
No Data